Recombinant Mouse Claudin-18.2 (Cldn18.2)-VLPs (Active)

Claudin-18.2 has emerged as a high-priority therapeutic target in oncology due to its restricted expression pattern and tumor-specific accessibility, making functional protein reagents essential for antibody development campaigns. This recombinant mouse Cldn18.2 is presented as virus-like particles displaying the full-length protein (aa 1–264, Isoform A2.1), preserving native multi-pass transmembrane topology that conventional soluble constructs cannot achieve. Functional ELISA confirms robust binding to an anti-CLDN18.2 recombinant antibody with an EC50 of 6.115–11.01 ng/mL, providing a suitable basis for antibody screening, epitope binning, and validation of therapeutic candidates targeting this tight-junction protein. The VLP format, produced in mammalian cells with endotoxin levels below 1.0 EU/μg, supports use in tumor metastasis modeling, immune cell trafficking research, and integrin-ligand or selectin-ligand binding studies where conformationally accurate membrane protein presentation is critical.